Optimizing sequential treatment with anti-EGFR and VEGF mAb in metastatic colorectal cancer: current results and controversies.

摘要: Anti-EGFR mAb (cetuximab or panitumumab) and anti-VEGF (bevacizumab) are the two main targeted agents available for RAS wild-type (WT) metastatic colorectal cancer (mCRC) treatment. Nonetheless, three head-to-head clinical trials evaluating anti-EGFR vs -VEGF in first-line treatment failed to conclude a uniform result. Recently, few small studies revealed that prior use of bevacizumab may impair effect cetuximab panitumumab. Preclinical have also suggested pretreatment with lead simultaneous resistance mAb. Therefore, we performed this review summarize data regarding optimal sequential KRAS WT mCRC discuss potential mechanisms explain phenomenon. Primary tumor location early shrinkage emerged as new prognostic predictive factors mCRC. We collected information explore whether these affect sequencing therapy However, definite conclusions cannot be made, can only speculate on recommendations based contradictory results.